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Abstract
Background: Seasonal and 2009 H1N1 influenza viruses may cause severe diseases and result in excess hospitalization and
mortality in the older and younger adults, respectively. Early antiviral treatment may improve clinical outcomes. We
examined potential outcomes and costs of test-guided versus empirical treatment in patients hospitalized for suspected
influenza in Hong Kong.
Methods: We designed a decision tree to simulate potential outcomes of four management strategies in adults hospitalized
for severe respiratory infection suspected of influenza: ‘‘immunofluorescence-assay’’ (IFA) or ‘‘polymerase-chain-reaction’’
(PCR)-guided oseltamivir treatment, ‘‘empirical treatment plus PCR’’ and ‘‘empirical treatment alone’’. Model inputs were
derived from literature. The average prevalence (11%) of influenza in 2010–2011 (58% being 2009 H1N1) among cases of
respiratory infections was used in the base-case analysis. Primary outcome simulated was cost per quality-adjusted life-year
(QALY) expected (ICER) from the Hong Kong healthcare providers’ perspective.
Results: In base-case analysis, ‘‘empirical treatment alone’’ was shown to be the most cost-effective strategy and dominated
the other three options. Sensitivity analyses showed that ‘‘PCR-guided treatment’’ would dominate ‘‘empirical treatment
alone’’ when the daily cost of oseltamivir exceeded USD18, or when influenza prevalence was ,2.5% and the predominant
circulating viruses were not 2009 H1N1. Using USD50,000 as the threshold of willingness-to-pay, ‘‘empirical treatment
alone’’ and ‘‘PCR-guided treatment’’ were cost-effective 97% and 3% of time, respectively, in 10,000 Monte-Carlo
simulations.
Conclusions: During influenza epidemics, empirical antiviral treatment appears to be a cost-effective strategy in managing
patients hospitalized with severe respiratory infection suspected of influenza, from the perspective of healthcare providers
in Hong Kong.
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Introduction
Seasonal influenza results in excess hospitalization and mortal-
ity, with highest risk for young children, adults aged $65 years and
patients with chronic medical conditions [1]. In 2009, a novel
influenza A(H1N1) virus of swine origin had caused a pandemic
[2–3]. The virus has continued to co-circulate with the seasonal
influenza viruses in many parts of the world, in varying
proportions. The key epidemiological feature of this novel
infection is that younger adults ,65 years are more commonly
infected, and they too may develop severe and fatal diseases, even
in the absence of underlying medical conditions [3]. Mortality
rates of 2009 H1N1 influenza and seasonal influenza for
hospitalized patients were estimated to be 2–15% and 3–8%
respectively [4–6]. Most fatal cases of 2009 H1N1 influenza were
aged 18–49 years [7].
A number of recent studies reported that early neuraminidase-
inhibitor treatment within 48 hours of onset was associated with
lower risks for disease progression and death in patients
hospitalized with seasonal or 2009 H1N1 influenza [3,6,8–14].
Given these potential benefits, most health authority guidelines
have suggested treatment for this patient group [2,3]. A rapid
clinical decision to treat hospitalized patients with suspected
influenza is therefore important. However, clinical features of
severe respiratory tract infection caused by influenza are
indistinguishable from other viral or bacterial pathogens, and
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influenza patients do not present with the typical ‘influenza-like
illness’) [3]. ‘Point-of-care’ rapid antigen tests for influenza are
known to have very low sensitivities [3,15]. More reliable rapid
diagnostic assays, such as immunofluorescence assay (IFA) and
Polymerase-Chain-Reaction (PCR), have been used to assist timely
diagnosis and management of hospitalized patients [15]. For
seasonal influenza, IFA has variable sensitivity (range 70–85%) but
high specificity (99%); its sensitivity for 2009 H1N1 influenza is
lower [16–18]. PCR is highly sensitive (.95%) and specific (98–
100%) for influenza virus infection [19–23], but its use is often
limited by the cost, as well as its availability and turn-around-time
in some hospitals. On the other hand, the empirical antiviral
treatment approach may offer timely therapeutic intervention to
patients, yet exposes many more patients without influenza to
antiviral agents. As there has been no consensus on the decision to
‘test’ or to ‘treat’ patients during influenza epidemics, we have
conducted this analysis to evaluate the potential costs and
outcomes of diagnostic test-guided and empirical antiviral
treatment approaches in patients hospitalized for severe respira-
tory infection suspected of influenza, from the perspective of
healthcare providers in Hong Kong.
Materials and Methods
Model Design
A decision tree was designed to simulate the outcomes of four
clinical management strategies in a hypothetical cohort of adult
patients hospitalized for severe respiratory infection, suspected of
influenza, including: (1) using IFA, or (2) PCR testing to guide
antiviral treatment; (3) empirical antiviral treatment plus PCR
testing, and later decide to continue or discontinue treatment
based on test results, and (4) empirical antiviral treatment alone
(Figure 1). Three tiers of outcomes were simulated for each study
arm: (1) total direct medical cost, (2) survival rate from influenza
infection, and (3) quality-adjusted life-years (QALYs) expected.
Case inclusion criteria were patients aged 18 years or above, had
symptoms and signs compatible with influenza (e.g. fever, cough)
and required hospitalization because of signs of severe lower
respiratory infection: hypoxemia, tachypnea, and/or pulmonary
infiltrates on chest radiography [8,24].
In the present model, hospitalized patients with severe
respiratory infection might or might not be infected with influenza
virus. Furthermore, those who had influenza infection might
present to the hospital within or beyond 48 hours from illness
onset, and they might be infected by either a ‘seasonal’ virus or the
2009 H1N1 virus. In the ‘IFA-guided treatment’’ arm, patients
with positive IFA test results would receive a course of oseltamivir.
Given the low negative-predictive value of IFA, clinicians might
still choose to treat despite a negative test result. In the ‘‘PCR-
guided treatment’’ arm, patients with positive PCR results would
receive a course of oseltamivir. Those who were test-negative
would not receive treatment because of the high negative-
predictive value of PCR. In the ‘‘empirical treatment plus PCR’’
arm, patients would receive empirical oseltamivir treatment and
also tested for influenza viruses by PCR. Oseltamivir would be
continued for the course if PCR result was positive, or
discontinued the next day if the result was negative. In the
‘‘empirical treatment alone’’ arm, all patients would receive a full-
course of oseltamivir. All patients who were infected with seasonal
or 2009 H1N1 influenza viruses might survive or die, with or
without being admitted to the Intensive Care Unit (ICU).
Clinical Inputs
The clinical inputs of the model were shown in Table 1.A
literature search on MEDLINE over the period of 2000–2011 was
performed. The selection criteria of clinical studies of seasonal and
2009 H1N1 influenza were: (1) reports were written in English; (2)
etiology of respiratory illnesses was identified to be seasonal or
2009 H1N1 influenza, and (3) mortality rate and/or ICU
admission rate were reported. All articles retrieved by this process
were screened for relevance to our model. A manuscript will be
included if it had data pertaining to the model inputs.
The effectiveness of early antiviral treatment for seasonal and
2009 H1N1 influenza was estimated by the mortality rate, and the
odds ratio of death associated with early antiviral treatment.
Surveillance data on influenza activity in Hong Kong indicated
that during 2010–2011, the prevalence of influenza A virus among
all causes of respiratory tract infections ranged from 0.1% in the
‘low’ season to about 30% in the ‘peak’ season (i.e. percentage test
positive among all clinical specimens obtained from symptomatic
individuals) [25]. In base-case analysis, the average prevalence
(11%) of influenza during the year was used to simulate the
treatment outcomes; in addition, the impact of prevalence levels at
low (0.1%) and peak (30%) seasons were examined in the
sensitivity analysis. The proportion of 2009 H1N1 virus among
all circulating influenza A viruses used in the base-case analysis
(58%) was derived from the 2010–2011 surveillance data; this
variable was examined over a wide range (0–97%) in the sensitivity
analysis [25]. Surveillance on oseltamivir resistance among the
influenza A viruses (seasonal strains and 2009 H1N1) isolated in
Hong Kong during 2010–2011 showed that all such isolates were
susceptible to oseltamivir [26]; about 0.7% of 2009 H1N1 viruses
were reported to be resistant to oseltamivir in the literature [27].
Thus the model input for oseltamivir susceptibility was 100% for
base-case analysis, and it was tested in the sensitivity analysis over
the range of 99.3%–100%.
Figure 1. Simplified Decision Tree.
doi:10.1371/journal.pone.0033123.g001
Test versus Treat Influenza CEA
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The QALYs expected by each influenza-infected patient was
estimated from the age of patient and potential life-years
expectancy surviving the infection. The utilities of adults aged
18–64 years and 65–85 years were retrieved from health-related
quality of life scores reported in literature [28]. The future
potential life-years gained were estimated using patient’s age and
life expectancy [29], and were discounted using a 3% discount rate
per year.
Cost Inputs
The economic analysis was conducted from the perspective of
Hong Kong healthcare providers. A patient infected with
influenza virus might be admitted to ICU, depending on the
probability of ICU admission for seasonal or 2009 H1N1 influenza
(and odds ratios of ICU admission after receiving early antiviral
treatment). The model inputs for costs of managing respiratory
infections were retrieved from our previous cost analysis of
influenza with hospitalization [30]. The cost of ICU care versus
non-ICU care was adjusted by a factor of 5 (ranging from 4–6), as
Table 1. Model inputs.
Base-case value
Range of sensitivity
analysis References
Clinical inputs
Prevalence of influenza infections in admitted patients with suspected influenza 11% 0.1%–30% [25]
Proportion of 2009 H1N1 influenza infections in admitted patients with influenza A infection 58% 0%–97% [25]
Proportion of patients with influenza infections presented within 48 hours of onset 50% 0–100% [14]
Susceptibility of influenza A viruses to oseltamivir 100% 99.3%–100% [26–27]
ICU admission rate
Seasonal influenza with late or no antiviral treatment 10.5% 3.1%–16.4% [4,14,35]
Odds ratio with early antiviral treatment 0.93 0.46–1.8 [14]
2009 H1N1 influenza with late or no antiviral treatment 11.4% 10.5%–12.2% [4,36]
Odds ratio with early antiviral treatment 0.68 0.47–0.99 [36]
Morality rate
Seasonal influenza with late or no antiviral treatment 4.9% 2.4%–10% [4,8,14]
Odds ratio with early antiviral treatment 0.20 0.06–0.80 [8–9,14]
2009 H1N1 influenza with late or no antiviral treatment 10% 2.2%–22.8% [4–7,10–11]
Odds ratio with early antiviral treatment 0.26 0.08–0.63 [10–11]
Sensitivity of diagnostic test
IFA for seasonal influenza 79.2% 70%–85% [16–17]
IFA for 2009 H1N1 influenza 50% 25%–75% [18]
PCR for seasonal influenza 99% 98%–100% [19–21]
PCR for 2009 H1N1 influenza 98% 86%–100% [22–23]
Clinical judgment on influenza 44% 25%–75% [37]
Specificity of diagnostic test
IFA for influenza 99% 80%–100% [16–17]
PCR for l influenza 97% 89%–100% [19–21]
Clinical judgment on influenza 57% 25%–75% [37]
Utility Inputs
Utility score
18–64 years 0.92 - [28]
65–85 years 0.84 - [28]
Mean age of patients hospitalized with seasonal influenza 70 18–80 [35,38]
Mean age of patients hospitalized with 2009 H1N1 influenza 47 18–70 [5,10]
Cost Inputs (USD)*
Oseltamivir (per day) 6 5–9 -
Duration of oseltamivir treatment (days) 5 5–10 [39]
PCR 25 20–30 Expert opinion
IFA 10 5–10 Expert opinion
Hospitalization of influenza with no ICU care 7,957 17,955–26,932 [30]
Adjusting factor for cost of hospitalization with ICU care 5 4–6 -
*1 USD=7.8 HK.
doi:10.1371/journal.pone.0033123.t001
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approximately 5-fold of the daily cost of non-ICU care. The daily
drug cost (USD5.8) of oseltamivir 75 mg twice daily therapy was
retrieved from local retail pricing of oseltamivir. The treatment
course of oseltamivir was 5 days in the base-case analysis (range 5–
10 days). The costs (including reagents and manpower) of PCR
and IFA with turn-around-time of less than 12 hours were derived
from literature [31], and expert opinion. All costs were discounted
to year 2011 costs with 3% discount rate.
Cost-effectiveness analysis and Sensitivity Analysis
A treatment strategy was dominated when it was more costly
and gained less QALYs than another treatment option. The
incremental cost per QALY gained (ICER) of each arm (excluding
the dominated strategy), comparing to the next less costly arm, was
calculated using the following equation: Dcost/DQALYs. Using
the threshold of USD50,000 as the willingness-to-pay per QALY
[32], the most effective strategy with ICER USD50,000 or less was
considered as cost-effective.
Sensitivity analysis was performed by TreeAge Pro 2009
(TreeAge Software, Inc., Williamstown, MA, USA) and Microsoft
Excel 2007 (Microsoft Corporation, Redmond, WA, USA) to
examine the robustness of the model results. All the parameters
were examined over the upper and lower limits of the variables, if
available. Otherwise, a range of variation by 620% of the base-
case value was used.
One-way sensitivity analysis on all variables was performed to
screen for potential influential factors. To evaluate the impact of
the uncertainty in all of the variables simultaneously, a
probabilistic sensitivity analysis was performed using Monte Carlo
simulation. The cost and QALYs of each study arm were
recalculated 10,000 times by simultaneously varying the values
of each model input through the ranges of sensitivity analysis to
determine the percentage of time in which each study arm would
be the most cost-effective option.
Results
Base-case analysis
In the base-case analysis (Table 2), it was shown that the
QALY expected from surviving influenza infection in the
‘‘empirical treatment alone’’ study arm was highest (1.6917
QALYs), and that it was the least costly option (USD 1,247).
The other three options including ‘‘IFA’’ (1.6731 QALYs, USD
1,249), ‘‘PCR-guided treatment’’ (1.6907 QALYs, USD 1,248)
and ‘‘empirical treatment plus PCR’’ (1.6907 QALYs, USD 1,253)
were all dominated by ‘‘empirical treatment alone’’.
Sensitivity analysis
The one-way sensitivity analysis had identified two influential
model inputs on the ICER of ‘‘empirical treatment alone’’: (1)
prevalence of influenza in patients hospitalized for severe
respiratory tract infections, and (2) proportion of 2009 H1N1
among all cases of influenza infections. A two-way sensitivity
analysis was then conducted (Figure 2): ‘‘empirical treatment
alone’’ was found to be the most cost-effective option in majority
of the combinations of these two variables. Only when the
prevalence of influenza was relatively low (,2.5%) and great
majority of the circulating viruses were seasonal influenza strains,
or when the influenza prevalence was extremely low (,0.4%) with
high proportion of 2009 H1N1, the additional cost per QALY
expected by ‘‘empirical treatment alone’’ would exceed
USD50,000, and ‘‘PCR-guided treatment’’ would become the
most cost-effective option with highest QALYs expected and
additional cost per QALY less than USD50,000. All other options
were dominated by either ‘‘empirical treatment alone’’ or ‘‘PCR-
guided treatment’’ throughout the variations of these two variables
in the model. We also examined the impact of the daily cost of
antiviral treatment as it has been reported to be an influential
factor on the cost-effectiveness of influenza treatment in literature
[33]. The range of daily drug cost was extended and tested in one-
way sensitivity analysis. It was found that ‘‘empirical treatment
alone’’ would be dominated by ‘‘PCR-guided’’ when the daily cost
of oseltamivir exceeded USD18.
In the 10,000 Monte Carlo simulations generated by probabi-
listic sensitivity analysis, ‘‘empirical treatment alone’’ dominated
the options of ‘‘IFA-guided treatment’’ and ‘‘empirical treatment
plus PCR’’. Comparing with the ‘‘PCR-guided treatment’’ option,
‘‘empirical treatment alone’’ was significantly more costly by
USD4.9 (95%CI=4.7–5.1), but with higher QALYs expected by
0.0029 QALYs (95%CI=0.0028–0.0030) (p,0.001). The prob-
abilities of each strategy to be cost-effective were examined in
acceptability curves over a wide range of willingness-to-pay per
QALY, from USD0-50,000 (Figure 3). Using USD50,000 as the
threshold of willingness-to-pay, the probabilities of ‘‘empirical
treatment alone’’ and ‘‘PCR-guided treatment’’ strategies to be
most cost-effective were 97% and 3%, respectively.
Discussion
The present study examined the cost-effectiveness of ‘empirical’
versus ‘test-guided’ influenza treatment strategies, at different
levels of influenza prevalence and combinations of circulating
viruses, in hospitalized adults with severe respiratory tract infection
suspected of influenza. Our results suggested that in a season when
the ‘seasonal influenza’ virus strains are predominant, ‘‘empirical
antiviral treatment alone’’ would be a cost-effective option at
influenza prevalence levels of 2.5% or above, whereas the ‘PCR-
guided treatment’ approach would be cost-effective at a low
prevalence of less than 2.5%. On the other hand, if 2009 H1N1
was predominating, ‘empirical treatment alone’ would be the more
cost-effective option over a wide range of influenza prevalence
levels (from 0.4% to .25%) as indicated by the two-way sensitivity
analysis.
We found that in times of lower influenza prevalence (,2.5%),
despite higher QALYs expected, the benefit of empirical treatment
did not outweigh the cost of antivirals given to all hospitalized
patients with respiratory infections suspected of influenza; the
‘‘PCR-guided treatment’’ approach was comparatively more cost-
Table 2. Results of base-case analysis on costs, survival event
rates and QALYs expected from surviving influenza infections
among hospitalized adults.
Strategy
Cost
(USD)
Survival
rate
a QALYs
b ICER
c (USD)
Empirical treatment alone 1,247 104.6 1.6917 -
PCR-guided treatment 1,248 104.5 1.6907 Dominated
IFA-guided treatment 1,249 103.8 1.6731 Dominated
Empirical treatment plus PCR 1,253 104.5 1.6907 Dominated
a: Survivals of influenza infection per 1,000 patients presented with suspected
influenza.
b: Quality-adjusted life-years (QALYs) expected from patients infected with
influenza A viruses.
c: ICER=increment cost per QALY gained.
doi:10.1371/journal.pone.0033123.t002
Test versus Treat Influenza CEA
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or above, the empirical treatment approach would enable more
patients to receive early therapeutic intervention within the first
48 hours of illness onset. The potential benefits of reduced ICU
admissions and mortality among these hospitalized patients
narrowed down the cost difference and increased the QALY gap
between the two approaches, especially when 2009 H1N1 virus
was the predominant circulating virus (which predominantly
affected the younger adults). The robustness of empirical
treatment being cost-effective was indicated by the Monte Carlo
10,000 simulations that the probability of ‘‘empirical treatment
alone’’ to be cost-effective in 97% of suspected cases. The ‘‘IFA-
guided treatment’’ was consistently dominated, which likely was
the results of the relatively low diagnostic accuracy for influenza
infections. ‘‘Empirical treatment plus PCR’’ was also dominated as
a result of increasing treatment cost without significant change in
QALYs, when compared with ‘‘PCR-guided treatment’’.
Lee et al. had compared the cost-effectiveness of empirical
intravenous (IV) peramivir alone, empirical peramivir plus PCR
and PCR-guided peramivir for patients hospitalized with influen-
Figure 2. Two-way sensitivity analysis of prevalence of influenza and proportion of 2009 H1N1 infections on ICER per QALY
expected by ‘‘empirical treatment alone’’ versus ‘‘PCR-guided treatment’’.
doi:10.1371/journal.pone.0033123.g002
Figure 3. Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay per QALY.
doi:10.1371/journal.pone.0033123.g003
Test versus Treat Influenza CEA
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cost-effective, followed by empirical treatment alone. Empirical
treatment plus PCR was found to be the least cost-effective option
[33]. Different from their findings, our base-case analysis showed
that empirical treatment alone was the more cost-effective option.
It was likely due to the large cost difference between IV peramivir
(USD20-1,000 per day) and oral oseltamivir (USD5.8 per day). In
our one-way sensitivity analysis, the ‘‘PCR-guided treatment’’
strategy became the most cost-effective when the daily cost of
oseltamivir was extended to USD18 and above, consistent with the
findings of Lee et al. Our results also showed that ‘‘empirical
treatment plus PCR’’ was less cost-effective than the ‘‘empirical
treatment alone’’ and ‘‘PCR-guided treatment’’ options. Similar to
our findings, empirical treatment was also more cost-effective than
the diagnostic test-guided strategy for influenza in pediatric
patients [34].
With new influenza virus strains emerging and increasing
clinical evidence on antiviral treatment benefits, the management
of patients hospitalized with influenza is evolving. Our decision
analysis compared the potential changes in economic and clinical
outcomes of four most commonly used management strategies in
patients hospitalized with suspected influenza at a wide range of
influenza prevalence levels, with varying combinations of circu-
lating virus strains. The results suggested that ‘‘empirical treatment
alone’’ is a cost-effective strategy in most situations during times of
epidemics based on the key performance indexes (cost, QALYs,
survival); however, the differences between the study arms are
small and we acknowledge that clinical needs and practicability in
individual settings are also important considerations. It should be
emphasized that our results do not argue against the clinical use of
laboratory tests for the management of individual patient
hospitalized for severe influenza infection, or for the purpose of
resistance monitoring [2]. Importantly, our decision model
provides a framework to examine the influential factors and the
corresponding threshold values (if any) for each strategy to
translate into a cost-effective option. The present findings, in
combination with real-time epidemiologic data through continu-
ous surveillance, may assist the informed decision-making process
of healthcare providers in future influenza seasons.
The present model was limited by sources of clinical model
inputs which were mostly obtained from retrospective observa-
tional studies. The model inputs was therefore examined over a
wide range in the sensitivity analyses to identify influential factors
that would alter the base-case findings. In our analysis, we had
assumed that a PCR assay’s turn-around-time was less than
12 hours. However in many institutes, access to PCR could be
limited and the results delayed for 1–2 days, or even longer. This
could lower the QALYs gained and increase the total cost, further
widening the cost and QALY differences between the comparative
arms. The side-effects of oseltamivir are generally mild (e.g. GI
intolerance), and therefore their impacts on cost and QALYs were
not considered in the models. The variable of bacterial co-
infection was also not included in the models for analysis due to
the complexity of ‘community-acquired’ versus ‘hospital-acquired’
infections, and their highly variable prevalence and resistance
profiles in different healthcare settings; also presence of bacterial
co-infection should not alter the decision to initiate antivirals in
influenza infection [7,13]. The surveillance in Hong Kong showed
that influenza A viruses are highly susceptible to oseltamivir
(nearly 100%). Data from continuing surveillance should be used
to update the impact of influenza viruses resistance on the decision
analysis.
In conclusion, during influenza epidemics with prevalence
.2.5%, empirical antiviral treatment appears to be a more cost-
effective strategy in managing patients hospitalized with severe
respiratory infection suspected of influenza, from the perspective
of healthcare providers in Hong Kong.
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